Clinical Trial Update: Evaluate the Safety and Exploratory Efficacy of GC1119 [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating GC1119 for Fabry disease has completed. The study assessed safety and exploratory efficacy of GC1119.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• GC1119

Snippet

Sponsor: Green Cross Corporation | Conditions: Fabry Disease | Phase 1 | Status: COMPLETED